Fig. 5.

ARD-61 induces apoptosis in AR+ breast cancer cell lines with high levels of AR expression. (A) MDA-MB-453, HCC1428 and MCF-7 cells were treated with different concentrations of ARD-61, 10 µM enzalutamide (Enza) or 10 µM AR antagonist ARi-16 for 72 h. (B) MDA-MB-453 and HCC1428 cells were treated with 1 µM ARD-61 for indicated time points. For apoptosis analysis, data were acquired on a flow cytometer and analyzed using Flowjo software. Percentages of live and apoptosis cells were plotted using Prism 8.0. Data were presented as mean ± SEM (n = 3). (C, D) MDA-MB-453 and HCC1428 cells were treated with different concentrations of ARD-61 or enzalutamide (Enza) for 48 h. Whole protein lysates were used for Western blot analysis.